Q-omics provides the consensus-scored SLAMF6P1 profile across patient tissues and cancer cell-line models. SLAMF6P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLAMF6P1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SLAMF6P1 RNA expression shows 7,772 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, KIRC, and ESCA as cancer lineages where SLAMF6P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLAMF6P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLAMF6P1 survival associations across molecular data types. SLAMF6P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLAMF6P1 RNA expression–survival associations across cancer types. High SLAMF6P1 expression shows unfavorable associations in KIRP, LUAD, DLBC and ESCA, but favorable associations in SKCM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLAMF6P1 RNA expression.
This table summarizes SLAMF6P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLAMF6P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLAMF6P1 shows lower tumor expression in KIRC, COAD, KIRP, HNSC and READ and higher tumor expression in LUAD. The KIRC box plot shows higher SLAMF6P1 RNA expression in normal versus tumor tissue (log2 FC = −0.783, t-test p < 0.001).
This table shows molecular features associated with SLAMF6P1 in patient tissues and cancer cell lines. In patient samples, SLAMF6P1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
